NCT06432621View on ClinicalTrials.gov

Role of Sugammadex and Neostigmine for Recovery From Rocuronium

NAActive, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

July 1, 2024

Study Completion Date

August 1, 2024

Conditions
Anesthesia
Interventions
PROCEDURE

using of sugammadex and neostigmine for reversal from rocuronium and assessment of response using ultrasound and nerve stimulation

patients will be randomly divided into two groups using a computer generated random number chart. Group S will receive sugammadex for reversal of rocuronium, whereas Group N will receive neostigmine for reversal of rocuronium using nerve stimulation and ultrasound to asses recovery of respiratory muscle

Trial Locations (1)

Unknown

Faculty of Medicine, Ain Shams University, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT06432621 - Role of Sugammadex and Neostigmine for Recovery From Rocuronium | Biotech Hunter | Biotech Hunter